Long-term Cardiac Monitoring in Epilepsy

NATerminatedINTERVENTIONAL
Enrollment

7

Participants

Timeline

Start Date

March 19, 2019

Primary Completion Date

November 1, 2022

Study Completion Date

January 3, 2023

Conditions
Focal EpilepsyIntractable EpilepsyEpileptic EncephalopathyLennox Gastaut SyndromeSymptomatic EpilepsyGeneralized Epilepsy
Interventions
DEVICE

Reveal LINQ ICM System

The LINQ ICM (Medtronic, Inc.) is a small FDA approved cardiac monitor implanted in the subcutaneous tissue of the chest wall that is designed to continuously record a single-lead ECG, monitoring the cardiac rhythm for up to three years. The device records and stores patient's rhythm on two occasions: first when programmed criteria are met and second upon patient activation. These programmable arrhythmia criteria are based on heart rate (bradycardia, tachycardia), irregularity of heart rate and duration of rate disturbance. The LINQ ICM (or future iterations) will be utilized in this study to detect arrhythmias in our study population.

Trial Locations (1)

10075

Northwell, New York

Sponsors

Lead Sponsor

Collaborators (1)

All Listed Sponsors
collaborator

Medtronic

INDUSTRY

lead

Northwell Health

OTHER

NCT03955432 - Long-term Cardiac Monitoring in Epilepsy | Biotech Hunter | Biotech Hunter